ate stent thrombosis after drug-eluting stent (DES) placement has emerged as a major concern. 1, 2 Clopidogrel plus aspirin is a standard regimen after coronary stent implantation because the side-effects of clopidogrel are less frequent than those of ticlopidine. 3 Early experience of coronary stents demonstrated efficacy of ticlopidine plus aspirin in preventing stent thrombosis after bare metal stent implantation. However, because there is little information about the efficacy of ticlopidine plus aspirin after DES implantation, we evaluated the incidence of stent thrombosis in patients receiving this combination after sirolimus-eluting stent (SES) implantation.
The present study included all consecutive patients (n=1,029) who underwent SES implantation in 3 Japanese centers (Chiba University Hospital, Chiba Cardiovascular Center, and Kimitsu Central Hospital) between August 2004 and September 2006. The study was approved by the local council on human research. Percutaneous coronary intervention (PCI) was performed after written informed consent was given. All interventions were performed according to current standard guidelines. All patients received aspirin 100 mg daily before the procedure and continued indefinitely. Patients were treated concomitantly with ticlopidine 100 mg twice daily (standard dose in Japan) 3 records and procedural reports. Clinical follow-up data were obtained from outpatient record reviews or telephone interviews. General practitioners, referring cardiologists, and patients were contacted as necessary for additional information. The occurrence of major late clinical events was recorded, including death (all-cause or cardiac), myocardial infarction (MI), and target lesion revascularization (TLR); these were adjudicated by accompanying source documentation. Stent thrombosis was defined as (1) the presence of an acute coronary syndrome with angiographic or autopsy evidence of thrombus or occlusion, (2) unexplained deaths within 30 days after the procedure or (3) acute MI involving the target-vessel territory without angiographic confirmation. Stent thrombosis was also classified as early (0-30 days), late (31-360 days) and very late (>360 days). Baseline clinical, angiographic, and procedural characteristics are shown in Table 1 . There were 3 in-hospital deaths (0.3%), none of which were associated with PCI. One patient (0.1%) had a procedural Q-wave MI. Follow-up was complete for 98.9% of the population. Mean follow-up was 17.0±7.9 months. During follow-up, there were 6 cardiac (0.6%) and 15 non-cardiac deaths (1.5%). Sudden unexplained death occurred in 2 patients (10 and 22 months after SES implantation). One of the cases occurred 7 months after undergoing TLR for in-stent restenosis 3 months after SES deployment. MI occurred in 8 patients (0.78%). TLR was performed in 57 lesions (5.4%). Major adverse cardiac events occurred in 79 patients (7.7%).
Early stent thrombosis occurred in 5 patients (0.49%): 1 patient who died and 4 with MI. There was 1 case each of late (0.1%) and very late stent thrombosis (0.1%); 1 patient had acute ST-segment elevation MI 10 days after cessation of dual antiplatelet therapy, because of pulmonary hemorrhage, 7 months after SES deployment and the other patient had been on aspirin monotherapy after 9-month follow-up angiography that demonstrated no restenosis. He had acute ST-segment elevation MI 26 months after SES deployment.
In both patients coronary angiography demonstrated stent thrombosis, which was successfully treated by PCI.
Late stent thrombosis after intravascular brachytherapy has been of concern. 4 Greater attention is paid to late stent thrombosis in the DES era, 1,2 because DES not only inhibits intimal hyperplasia, but also delays reendothelialization. [5] [6] [7] A registry totaling 81 human autopsies of DES implanted >30 days reported less reendothelialization in lesions with than without stent thrombosis. 5 Recently, a serial angioscopy study 6 has demonstrated incomplete neointimal coverage 21.2±2.2 months after SES implantation. The reported incidence of late stent thrombosis after DES implantation in patients receiving clopidogrel plus aspirin ranged between 0.3% and 0.7%. 1, 2 There is little information about stent thrombosis after DES implantation in patients receiving ticlopidine plus aspirin. The Taxus in Real-life Usage Evaluation (TRUE) study 8 evaluated the safety and efficacy of clopidogrel plus aspirin (n=393) vs ticlopidine plus aspirin (n=112) after paclitaxel-eluting stent implantation. There was no significant difference in subacute stent thrombosis between the 2 groups (0.5% vs 0%, p=1.0). There was no late stent thrombosis in the clopidogrel group. In the ticlopidine group, late stent thrombosis occurred in 2 patients (1.8%) with premature ticlopidine withdrawal; no patients on dual antiplatelet therapy of ticlopidine plus aspirin had late stent thrombosis.
After coronary stenting, ticlopidine plus aspirin is still used in Japan because clopidogrel was not available until May 2006 and it is still off-label for prevention of stent thrombosis. Takahashi et al 9 reported 4 cases (0.6%) of late stent thrombosis out of 725 patients who had undergone SES implantation and received ticlopidine and aspirin. The details of each case were presented: 3 of the 4 patients had premature discontinuation of antiplatelet therapy; however, the clinical, angiographic, and procedural characteristics of the 725 patients were not available. Recently, Mutoh et al 10 reported a TLR rate of 9.3% in 1,070 lesions that had SES deployment. They also presented no documented late stent thrombosis in 2,166 lesions with SES; however, clinical, angiographic, and procedural characteristics, as well as follow-up rate and duration, for the 2,166 lesions were not presented, although the data for the 1,070 lesions were available.
It is a limitation that follow-up data are collected retrospectively. The standard dose of ticlopidine in Japan (100 mg twice daily) is lower than that in US and Europe. Racial differences in thrombogenicity might exist and explain the low rates of late and very late stent thrombosis in Japanese patients receiving ticlopidine and aspirin after SES deployment. The incidence of stent thrombosis in Japanese patients receiving clopidogrel plus aspirin after SES implantation should also be investigated.
The present study shows that late and very late stent thrombosis in Japanese patients receiving ticlopidine plus aspirin after SES implantation occurs infrequently.
